Proactive Investors - Run By Investors For Investors

GeoVax partners with Univ. of Georgia to speed up vaccine against Zika virus

GeoVax Labs, a biotechnology company famous for developing human vaccines against HIV, has teamed up with the University of Georgia to speed up development of a vaccine for the prevention of infection from the Zika virus.
GeoVax partners with Univ. of Georgia to speed up vaccine against Zika virus
GeoVax hopes initiative will speed up Zika vaccine

Biotech company GeoVax Labs (OTCMKTS: GOVX) has teamed up with the University of Georgia to speed up development of a vaccine for the prevention of infection from the Zika virus.

GeorgeVax, established primarily to develop an effective and safe vaccine against HIV-1, ultimately aims to create vaccines for many serious human diseases for which none currently exist, such as Zika. It will use its MVA-VLP vaccine platform in the quest and hopes to rapidly advance a vaccine to human clinical testing.

On February 1, the World Health Organization (WHO) designated the Zika virus and its suspected complications in newborns an international public health emergency. The Zika epidemic, currently in 24 countries in the Americas, is transmitted by the Aedes mosquito and is expected by the WHO to reach most of the Western Hemisphere, infecting up to 4 million people by year's end. 

The Centers for Disease Control and Prevention has issued a travel advisory for people traveling to regions within the Zika virus outbreak, which include popular vacation destinations. Brazil, the site of the 2016 Summer Olympic Games, is included in the advisory. More than 30 cases have been reported in the United States, imported by travelers visiting affected regions.

GeoVax's senior vice president of Research and Development, Farshad Guirakhoo, PhD, will lead the company's effort in developing a Zika virus vaccine. Dr Guirakhoo played pivotal roles in the development and licensure of human vaccines against Flaviviruses including dengue and Japanese encephalitis. His experience and expertise with Flavivirus vaccine development gives the company an advantage over competitors and will shorten the time until a Zika vaccine can be brought to market by GeoVax and its partners, the company said.

In that vein, GeoVax has entered into a Collaborative Research Agreement with the University of Georgia.

Other than mosquito control, no approved preventive or therapeutic products are currently available to fight Zika infections. Public health officials recommend avoiding exposure to Zika, delaying pregnancy, and following basic supportive care after infection. A vaccine is urgently needed to prevent a Zika pandemic.

On Wednesday, media reported an incidence of Zika being spread through sexual contact, in a case in Dallas, United States.

Shares in Atlanta-based GeoVax advanced 21%, or 2 cents, to US$0.10.

 

View full GOVX profile View Profile

GeoVax Labs Timeline

Newswire
March 07 2016

Related Articles

A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use